Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Show all 180 references

Sorted by citations

Items 501–600 of 946

Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions
Rein, H. L., Rawal, Y., Palovcak-Lightbourn, A. L., Ganesan, G. S., Parker, P. S., Russell, R. A., Darrah, K. E., Afsar, M., Sullivan, M. R., Hengel, S. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61283-2 · Cited by 10
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers
Xu, Q., Wen, Y., Huang, T., Li, H., Liu, X., Shi, S.-N., Gong, W., Mills, G. B., Ma, D., Gao, Q., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00814-x · Cited by 10
Radiomics and radiogenomics in ovarian cancer: a review with a focus on ultrasound applications
Huang, Y., Peng, W., Yang, H., Liu, Z., Zhang, T., Jin, L., He, W., Du, M., & Chen, Z. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00950-5 · Cited by 10
Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes
Pérez‐Villatoro, F., Shabanova, A., van Wagensveld, L., Junquera, A., Niemiec, I., Hincapié-Otero, M. M., Kang, Z., Falco, M. M., Birgin, K., Wolf, S., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1492 · Cited by 10
A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients
Chen, Y., Zheng, X., Lin, J., Gao, X., Xiong, J., Liu, J., Fei, Z., & Chen, C. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105860 · Cited by 10
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Bouberhan, S., Bar‐Peled, L., Matoba, Y., Mazina, V., Philp, L., & Rueda, B. R. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.146 · Cited by 10
The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
Zielli, T., Labidi‐Galy, S. I., Grande, M. D., Sessa, C., & Colombo, I. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.08 · Cited by 10
Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
Ferreyra, Y., Rosas, G., Cock-Rada, A. M., Araujo, J. M., Bravo, L., Doimi, F. D., Casas, J., Clavo, M. D. L. Á., Pinto, J. A., & Belmar-López, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227864 · Cited by 10
RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis
Tsantikidi, A., Papazisis, K. T., Floros, T., Gazouli, M., Papadopoulou, E., Tsaousis, G., Nasioulas, G., Meşter, A., Milan, K., Gozman, B., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.14060 · Cited by 10
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
Postel-Vinay, S. C., Coves, J., Texier, M., Aldea, M. D., Gazzah, A., Dómine, M., Planchard, D., Peñas, R. D. L., González, M. A. S., Viteri, S., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02514-5 · Cited by 10
αKG-mediated carnitine synthesis drives DNA repair via histone acetylation
Uboveja, A., Yang, B., Buj, R., Amalric, A., Wang, H., Tangudu, N. K., Cole, A. R., Disharoon, J. A., Fang, R. S., Levasseur, E., et al. (2026) · Nature · doi:10.1038/s41586-026-10584-7 · Cited by 10
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
Lorusso, D., Guy, H., Samyshkin, Y., Hawkes, C., Estenson, K., & Coleman, R. L. (2022) · Cancers · doi:10.3390/cancers14051285 · Cited by 10
Identification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes
Shen, X., Gu, X., Ma, R., Li, X., & Wang, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.772701 · Cited by 10
Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency
Guantay, L., Garro, C., Siri, S. O., Pansa, M. F., Ghidelli, S., Paviolo, N. S., Racca, A. C., Nicotra, V. E., Radu, C. G., Bocco, J. L., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100932 · Cited by 10
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications
McCann, K. E. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000517 · Cited by 10
The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian CancerPreprint
Launonen, I.-M. P., Vähärautio, A., & Färkkilä, A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041314 · Cited by 10
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review
Moore, K. N., & Pothuri, B. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000558 · Cited by 9
H2O2 promotes photodynamic efficacy of TMPyP4 against ovarian cancer in vitro by downregulating HIF-1α expression
Chen, K., Zhai, Y., Wang, Y., Xu, Z., Chen, X., Zhang, Y., Zhou, Z., Zheng, X., & Lin, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117110 · Cited by 9
Organoid modeling meets cancers of female reproductive tract
Li, J., Zhou, M., Xie, J. H., Chen, J., Yang, M., Ye, C., Cheng, S., Liu, M., Li, R., & Tan, R. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02186-x · Cited by 9
From fallopian tube epithelium to high-grade serous ovarian cancer: A single-cell resolution review of sex steroid hormone signaling
Gjorgoska, M., & Rižner, T. L. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101302 · Cited by 9
Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines
Dodson, A. E., Shenker, S., Sullivan, P., Nayak, S. U., Middleton, C., McGuire, M. S., Chipumuro, E., Mishina, Y., Tobin, E. R., Cadzow, L., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0316 · Cited by 9
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer
Conca, E., Lorenzini, D., Minna, E., Agnelli, L., Duca, M., Gentili, M., Beatrice, B., Polignano, M., Mantiero, M., Damian, S., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1633410 · Cited by 9
Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Amuzu, S., Carmona, E., Mes‐Masson, A., Greenwood, C. M. T., Tonin, P. N., & Ragoussis, J. (2021) · Cancers · doi:10.3390/cancers13061296 · Cited by 9
Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome
Dong, Q., Liu, M., Chen, B., Zhao, Z., Chen, T., Wang, C., Zhuang, S., Li, Y., Wang, Y., Ai, L., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.007 · Cited by 9
Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition
Siddiqui, A., Tumiati, M., Joko, A., Sandholm, J. A., Roering, P., Aakko, S., Vainionpää, R., Kaipio, K., Huhtinen, K., Kauppi, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.733700 · Cited by 10
Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
Zhang, M., Ma, S.-C., Tan, J.-L., Wang, J., Bai, X. T., Dong, Z., & Zhang, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772604 · Cited by 9
Establishment and validation of a prognostic model based on HRR-related lncRNAs in colon adenocarcinoma
Tang, X., Lin, Y., He, J., Luo, X., Liang, J., Zhu, X., & Li, T. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02534-0 · Cited by 9
Comprehensive Analysis of the Expression and Clinical Significance of a Ferroptosis-Related Genome in Ovarian Serous Cystadenocarcinoma: A Study Based on TCGA Data
Yang, H. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.026447 · Cited by 9
Comprehensive Review of Serous Tumors of Tubo-Ovarian Origin: Clinical Behavior, Pathological Correlation, Current Molecular Updates, and Imaging Manifestations
Folsom, S. M., Berger, J. L., Soong, T. R., & Rangaswamy, B. (2023) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2023.05.010 · Cited by 9
A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
Guarischi‐Sousa, R., Kroll, J. E., Bonaldi, A., Pierry, P. M., Villela, D., Souza, C. A., Silva, J. S., Bürger, M. C., Oliveira, F. D. A., Paula, M. G., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13213293 · Cited by 9
Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients
Kotoula, V., Lakis, S., Tikas, I. S., Giannoulatou, E., Lazaridis, G. T., Papadopoulou, K., Manoussou, K., Efstratiou, I., Παπανικολάου, Α., Fostira, F., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.016 · Cited by 9
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research
Washington, C. R., Gunderson, C. C., & Moore, K. N. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000507 · Cited by 9
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
Carlson, A. S., Acevedo, R. I., Lim, D. M., Gulati, R., Gawne, A. M., Sokolova, A. O., Cheng, H. H., Nelson, P. S., Montgomery, B., Yu, E. Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239686 · Cited by 9
Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
Su, R., Liu, Y., Wu, X., Xiang, J., & Xi, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.762741 · Cited by 9
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
Velázquez, C., Orhan, E., Tabet, I., Fenou, L., Orsetti, B., Adélaı̈de, J., Guillé, A., Thézenas, S., Lopez‐Crapez, E., Colombo, P., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125021 · Cited by 9
Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
Romeo, M., Pardo, J. C., Martínez‐Cardús, A., Martinez‐Balibrea, E., Quiroga, V., Martínez‐Román, S., Solé, F. G., Vila, M. M., & Mesı́a, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103249 · Cited by 10
PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673
Cao, P., Wang, Y., Lv, Y., Jiang, N., Zhong, L., Ma, X., Xiao, X., Ding, D., Gu, J., Lin, L., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7313 · Cited by 9
Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas
Page, C. L., Chung, J. W., Rahimi, K., Köbel, M., Provencher, D. M., & Mes‐Masson, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666191016143836 · Cited by 9
NF-κB-miR-155 axis activation mediates ovulation-induced oncogenic effects in fallopian tube epithelium
Brand, H., Barnabas, G. D., Sapoznik, S., Bahar‐Shany, K., Pozniak, Y., Yung, Y., Hourvitz, A., Geiger, T., Jacob‐Hirsch, J., & Levanon, K. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa068 · Cited by 9
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
Tsantikidi, A., Papadopoulou, E., Metaxa-Mariatou, V., Metaxa-Mariatou, V., Kapetsis, G., Florou-Chatzigiannidou, C., Meintani, A., Gazouli, M., PAPADIMITRIOU, C. A., Timotheadou, E. T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13182962 · Cited by 8
Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcomes
Schnaiter, S., Schamschula, E., Laschtowiczka, J., Fiegl, H., Zschocke, J., Zeimet, A. G., Wimmer, K., & Reimer, D. (2024) · Cancers · doi:10.3390/cancers16112129 · Cited by 8
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy
Gronauer, R., Madersbacher, L., Monfort‐Lanzas, P., Floriani, G., Sprung, S., Zeimet, A. G., Marth, C., Fiegl, H., & Hackl, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489235 · Cited by 8
Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?
Lønning, P. E., Nikolaienko, O., & Knappskog, S. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00746 · Cited by 8
PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer
Fang, T., Xia, Y., Li, Y., Xu, S., Li, H., Wang, S., Huang, P., Qian, Y., Jin, P., Jin, N. Y., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2516294 · Cited by 8
Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science
Menon, R. M., Bako, E., Liu, S., Stec, J. J., Thakur, S., Deutschman, E., Ab, O., & Jain, S. (2026) · Clinical and Translational Science · doi:10.1111/cts.70447 · Cited by 8
BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery
Trusler, O., Goodwin, J., & Laslett, A. L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188459 · Cited by 8
Assistance by Routine CT Features Combined With 3D Texture Analysis in the Diagnosis of BRCA Gene Mutation Status in Advanced Epithelial Ovarian Cancer
Li, M.-R., Liu, M., Ge, Y., Zhou, Y. Y., & Wei, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696780 · Cited by 8
Establishing Molecular Subgroups of CD8+ T Cell-Associated Genes in the Ovarian Cancer Tumour Microenvironment and Predicting the Immunotherapy Response
Zhu, Y., Liang, L., Li, J., Zeng, J., Yao, H., & Wu, L. (2023) · Biomedicines · doi:10.3390/biomedicines11092399 · Cited by 8
Carcinoma of the Ovaries and Fallopian Tubes
Coleman, R. L., Liu, J., Matsuo, K., Thaker, P. H., Westin, S. N., & Sood, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00086-4 · Cited by 8
Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis
Wu, Y., Wu, T., Hu, X., Xu, S., Xiao, D., Wu, J., Yan, X., Yang, X., & Li, G. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.67027 · Cited by 8
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers
Wolford, J. E., Ferrigni, E. N., Margul, D. J., & Herzog, T. J. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01163-2 · Cited by 8
Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells
Gu, W., Lin, J., & Hong, X. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20412 · Cited by 8
Pan-Cancer Molecular Biomarkers
Dong, F. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.012 · Cited by 8
The Application of Biomaterials in the Treatment of Platinum‐Resistant Ovarian Cancer
Levy, A., Leynes, C., Baig, M., & Chew, S. A. (2019) · ChemMedChem · doi:10.1002/cmdc.201900450 · Cited by 8
A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin
Santos, S. M., & Hartman, J. L. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0201-3 · Cited by 10
Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
Hongo, H., Kosaka, T., Aimono, E., Nishihara, H., & Oya, M. (2020) · Diagnostic Pathology · doi:10.1186/s13000-019-0916-z · Cited by 9
Ovarian Cancer TherapyPreprint
Miao, D., Matulonis, U. A., & Porter, R. L. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038232 · Cited by 9
Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study
Хохлова, С. В., Al-Naqqash, M. A., Bahaj, W., Bujassoum, S. M., Lee, J., Mokhtar, M., Tyulyandina, A. S., Malaga, C. L. V., & Wu, C. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101645 · Cited by 7
Interplay of replication stress response and immune microenvironment in high-grade serous ovarian cancer
Venegas-Godinez, L., & Lheureux, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1638964 · Cited by 7
RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors
Chandramouly, G., Fried, W., Gordon, J. C., Ralph, D., Keuk, C., Kumari, S., Ramanjulu, M. M., Auerbacher, W., Станиславович, М. Л., Tredinnick, T., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00551 · Cited by 7
Long read sequencing reveals novel genomic and epigenomic alterations in repetitive regions of high grade serous ovarian cancer
Takamatsu, S., Li, J., Welte, T., Khlebus, E., Vuttaradhi, V. K., Brodsky, A. L., Lawson, B. C., & Hillman, R. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-21907-5 · Cited by 8
Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure
Garg, P., Salgia, R., & Singhal, S. S. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02115-9 · Cited by 7
Bayesian Inference of Hub Nodes Across Multiple Networks
Kim, J., Do, K.-A., Ha, M. J., & Peterson, C. B. (2018) · Biometrics · doi:10.1111/biom.12958 · Cited by 7
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
Fujiwara, S. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad057 · Cited by 7
Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice
Elkatary, R., El-Beltagi, H., Abdo, V. B., Fatah, D. S. A. E., El-Karef, A., & Ashour, R. H. (2023) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2023.104261 · Cited by 7
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
Vendrell, J. A., Ban, I. O., Solassol, I., Audran, P., Cabello‐Aguilar, S., Topart, D., Lindet-Bourgeois, C., Colombo, P., Legouffe, É., D’Hondt, V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814181 · Cited by 7
Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOC Cells
Aydın, E. M., Canıtez, İ. S., Colombo, E., Princiotto, S., Passarella, D., Dallavalle, S., Christodoulou, M. S., & Durmaz, İ. (2023) · Molecules · doi:10.3390/molecules28237777 · Cited by 7
Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
Mirielle, C., Lavi, E. S., Altwerger, G. H., Lin, Z. P., & Ratner, E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305273 · Cited by 7
Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection
Schejbel, L., Poulsen, T. S., Vestergaard, L. K., Christensen, I. J., & Høgdall, E. V. S. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00745-7 · Cited by 7
Recent development of nanotechnology-based approaches for gynecologic cancer therapy
Gedda, G., Park, Y.-J., & Pang, M. (2024) · Obstetrics & Gynecology Science · doi:10.5468/ogs.24180 · Cited by 7
Germline variation of Ribonuclease H2 genes in ovarian cancer patients
Polaczek, R., Schürmann, P., Speith, L., Geffers, R., Dürst, M., Hillemanns, P., Park‐Simon, T., Liebrich, C., & Dörk, T. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00753-1 · Cited by 7
Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting
Zhong, Q., Xiong, Y., Ling, C., Qian, Y., Zhao, X., & Yang, H. (2021) · Experimental Biology and Medicine · doi:10.1177/1535370221994077 · Cited by 8
TdT-dUTP DSB End Labeling (TUDEL), for Specific, Direct In Situ Labeling of DNA Double Strand Breaks
Lutze, J., Warrington, S. E., & Kron, S. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1811-0_18 · Cited by 8
Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context
González-Martı́n, A., Matulonis, U. A., Korach, J., Mirza, M. R., Moore, K. N., Wu, X., York, W., Gupta, D., Lechpammer, S., & Monk, B. J. (2022) · Future Oncology · doi:10.2217/fon-2022-0206 · Cited by 7
HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data
Wang, X., Xu, Y., Zhang, Y., Wang, S., Zhang, X., Yi, X., Zhang, S., & Wang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.990244 · Cited by 7
Epigenetic basis for PARP mutagenesis in glioblastoma: A review
Anu, M., Xavier, J., S, F. A., Bisht, P., Murti, K., Ravichandiran, V., & Kumar, N. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175424 · Cited by 7
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis
Petrelli, F., Rea, C. G., Solinas, C., Ghidini, A., Borgonovo, K., Celotti, A., Villa, A., Luciani, A., & Lorusso, D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102571 · Cited by 7
Successful treatment of advanced squamous cell carcinoma arising from mature cystic teratoma of the ovary with homologous recombination deficiency
Tamura, R., Yamaguchi, M., Kitani, Y., Nishikawa, N., Kawasaki, T., & Kikuchi, A. (2023) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2023.108329 · Cited by 7
Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas
Kramer, C. J. H., Lanjouw, L., Ruano, D., ter Elst, A., Santandrea, G., Solleveld‐Westerink, N., Werner, N., van der Hout, A., de Kroon, C. D., van Wezel, T., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6218 · Cited by 9
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US
Wu, L., & Zhong, L. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1557199 · Cited by 7
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells
Zhai, B., Li, Y., Kotapalli, S. S., Bacha, J., Brown, D., Steinø, A., & Daugaard, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02780-8 · Cited by 7
RETRACTED ARTICLE: Automatic identification of drug sensitivity of cancer cell with novel regression-based ensemble convolution neural network model
Gadde, S., Charkravarthy, A. S. N., Satyanarayana, S., & Murali, M. (2022) · Soft Computing · doi:10.1007/s00500-022-07098-5 · Cited by 7
Retracted
The unveiled mosaic of intra-tumor heterogeneity in ovarian cancer through spatial transcriptomic technologies: A systematic review
Masatti, L., Marchetti, M., Pirrotta, S., Spagnol, G., Corrà, A., Ferrari, J., Noventa, M., Saccardi, C., Calura, E., & Tozzi, R. (2024) · Translational research · doi:10.1016/j.trsl.2024.08.001 · Cited by 6
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer
Cerra, C., Tancock, M. R. C., Thio, N., Koo, A., Wong, A., Cowley, K. J., Varshney, S., Willis, M. O., Simpson, K. J., Australian Ovarian Cancer Study Group, et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02716-1 · Cited by 6
Fanconi anemia associated protein 20 (FAAP20) plays an essential role in homology-directed repair of DNA double-strand breaks
Palovcak, A., Yuan, F., Verdún, R. E., Luo, L., & Zhang, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-05252-9 · Cited by 6
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer
Burdett, N. L., Willis, M. O., Pandey, A., Fereday, S., AOCS Study Group, Management Group, Bowtell, D. D. L., Chenevix‐Trench, G., Green, A. C., Webb, P. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48153-x · Cited by 6
Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients
Li, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05236-1 · Cited by 6
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Becker, O., Durand, A., Chevrier, M., Collet, L., Gladieff, L., Joly, F., Sauterey, B., Pomel, C., Costaz, H., Pautier, P., et al. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2024-005815 · Cited by 6
Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies
Wang, R., Liu, Y., Liu, M., Zhang, M., Li, C., Xu, S., Tang, S., Ma, Y., Wu, X., & Fei, W. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125028 · Cited by 6
Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma
Yeh, C., Lin, S., Wu, C.-L., Liou, M., Chen, C., Chang, C., Chang, C.-F., Wang, Q., & Wu, C. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00802-2 · Cited by 6
Distinct roles of the two BRCA2 DNA-binding domains in DNA damage repair and replication fork preservation
Neal, F. E., Li, W., Uhrig, M. E., Katz, J. N., Syed, S., Sharma, N., Dutta, A., Burma, S., Hromas, R., Mazin, A. V., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115654 · Cited by 6
Genetic Testing for Cancer Predisposition Syndromes in Adolescents and Young Adults (AYAs)
Cullinan, N. M., Capra, M. L., & McVeigh, T. P. (2020) · Current Genetic Medicine Reports · doi:10.1007/s40142-020-00187-7 · Cited by 6
BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
Liontos, M., Zografos, E., Zoumpourlis, P., Andrikopoulou, Α., Svarna, A., Fiste, O., Kunadis, E., Papatheodoridi, A. M., Kaparelou, M., Koutsoukos, K., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060377 · Cited by 6
Targeted Therapy and Molecular Genetics
Westin, S. N., Sood, A. K., & Coleman, R. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40067-1.00018-8 · Cited by 6
Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms
Garzón-Hernández, C., Ramírez-Merino, N., & Soberón, M. C. M. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.11.007 · Cited by 7
Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort
Radoi, V. E., Țurcan, M., Maioru, O., Dan, A., Bohîlțea, L. C., Dumitrescu, E., Gheorghe, A. S., Stănculeanu, D. L., Thodi, G., Loukas, Y. L., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13111896 · Cited by 6
Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency
Lin, H., Xie, Y., Kong, Y., Yang, L., & Li, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03432-3 · Cited by 6
Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis
Bak, S. E., Kim, H., Yoon, S. M., Cho, E., Lee, J., Youn, S. M., Park, S.-W., Han, M.-R., Hur, S. Y., Lee, S. J., et al. (2023) · Cancers · doi:10.3390/cancers15020530 · Cited by 6
Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays
Krumm, N., Khasnavis, N., Radke, M. R., Banda, K., Davies, H. R., Pennil, C. C., McLean, K., Paulson, V., Konnick, E. Q., Johnson, W. C., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00720 · Cited by 6
Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
Shoji, T., Sato, C., Tomabechi, H., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., & Baba, T. (2021) · Medicina · doi:10.3390/medicina57050501 · Cited by 6

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks